AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
AstraZeneca Plc (NASDAQ:AZN) and Sanofi SA (NASDAQ:SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory syncytial virus (RSV). The data showed that a single dose of nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% compared to…
Benzinga ·
Benzinga
